Revvity Unveils Several Next-Generation Preclinical Imaging Technologies to Help Scientists Drive Breakthrough Discoveries

Revvity, Inc. (NYSE: RVTY) today debuts its enhanced imaging portfolio designed to drive innovation across diverse applications in preclinical research with the launch of three systems. These new innovations include the next-generation IVIS Spectrum 2 and the IVIS SpectrumCT 2 imaging systems, further elevating versatility and sensitivity standards in in vivo optical imaging. Also launching is the Quantum^TM GX3 microCT structural imaging solution with increased resolution and speed for both in vivo and ex vivo imaging, designed to facilitate researchers studying disease biology or evaluating and fast-tracking therapeutic candidates. And making its global debut is the Vega ultrasound system, originally launched in North America in 2022. These cutting-edge technologies will be showcased at the World Molecular Imaging Congress (WMIC) being held September 5-9, in Prague, Czech Republic.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230905069162/en/

Revvity's new Quantum GX3 micro CT imaging solution (Photo: Business Wire)

According to Dr. Alan Fletcher, Senior Vice President of Life Sciences at Revvity, "In a time when innovative technologies steer medical advancements, we are committed to delivering versatile, high-throughput solutions that enhance preclinical R&D productivity. Our growing portfolio equips researchers with robust capabilities to illuminate scientific discoveries and can expedite the journey from discovery to cure."

IVIS Spectrum 2 and IVIS SpectrumCT 2 systems: next-level optical imaging

With 2D and 3D bioluminescence and fluorescence for in vivo imaging, this next-level IVIS platform builds upon the success of the widely-adopted previous generation instruments, which have been cited in over 15,000 peer-reviewed papers. Equipped with an exclusive state-of-the-art camera with eXcelon coating for even higher sensitivity imaging, and a posing station that drives high-throughput imaging and improved workflow, the IVIS Spectrum 2 platform facilitates longitudinal disease tracking, cell movement analysis, drug safety assessment, treatment efficacy evaluation, and exploration of biological processes at the molecular level — all in real-time and non-invasively. The system seamlessly integrates 2D optical and full 3D imaging, bolstered by high-throughput capabilities enabling simultaneous imaging of up to ten specimens. Throughput is further accelerated with the benchtop posing station and Smart Trays designed to streamline imaging workflow. For ultimate ease and flexibility, the IVIS SpectrumCT 2 system incorporates all the features of the IVIS Spectrum 2 platform with the addition of integrated, low-dose CT, bringing together functional and anatomical imaging into a single system.